trial · primary record
CT-P44(Daratumumab)
Refractory or Relapsed Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 473 |
| Primary completion | 2028-09-18 |
| Primary endpoint | PK equivalence of CT-P44 and Darzalex Faspro |
| Registry ID | NCT06952478 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:45.998Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06952478
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.